Cantargia AB Sustainability Reports
Cantargia AB is a biotechnology company focused on developing targeted antibody-based treatments for cancer and inflammatory diseases. Its primary research revolves around the IL1RAP protein platform to enhance therapeutic efficacy and block pro-inflammatory signals.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
ISIN: SE0006371126
11 reports from 2014 to 2025